![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/evommune-announces-positive-proof-of-concept-clinical-trial-results-for-its-mrgprx2-antagonist-evo756-302197451.html
https://www.prnewswire.com/news-releases/evommune-secures-exclusive-rights-to-develop-and-commercialize-a-phase-2-ready-il-18-targeted-fusion-protein-from-aprilbio-302179623.html
https://www.prnewswire.com/news-releases/evommune-announces-initiation-of-a-phase-1-trial-of-its-mrgprx2-antagonist-for-the-treatment-of-chronic-spontaneous-urticaria-302037378.html
https://www.prnewswire.com/news-releases/evommune-and-accutar-biotechnology-announce-ai-drug-discovery-collaboration-301996316.html
https://www.fiercebiotech.com/biotech/evommune-drops-irak4-inhibitor-after-assessing-phase-2-dermatitis-data
https://www.prnewswire.com/news-releases/evommune-announces-strategic-collaboration-with-maruho-to-develop-and-commercialize-mrgprx2-antagonist-evo756-in-japan-301939507.html
https://www.prnewswire.com/news-releases/evommune-adds-additional-investment-in-series-b-financing-and-bolsters-leadership-team-301865257.html
https://www.prnewswire.com/news-releases/evommune-initiates-phase-2a-proof-of-concept-clinical-trial-to-evaluate-evo101-in-atopic-dermatitis-301634974.html
https://www.prnewswire.com/news-releases/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101--an-irak4-inhibitor-in-healthy-volunteers-301506593.html